Tisotumab Vedotin is named as a drug or biological intervention in 2 clinical trials in our UK, USA, Ireland and China trial registers, none of which are currently recruiting. Lead sponsors include Merck Sharp & Dohme LLC (1) and Seagen, a wholly owned subsidiary of Pfizer (1). Registered phases: Phase 3 and Phase 2. Conditions studied include Cervical Cancer; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06459180 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) Cervical Cancer |
Phase 3 | Active, closed |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (ClinicalTrials.gov ↗) Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Cervical Cancer | 1 |
| Colorectal Neoplasms | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Exocrine Pancreatic Cancer | 1 |
| Carcinoma, Squamous Cell of Head and Neck | 1 |
| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 1 |
| Seagen, a wholly owned subsidiary of Pfizer | 1 |
| Register | Tisotumab Vedotin trials |
|---|---|
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
| Clinical trials in Ireland | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tisotumab Vedotin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tisotumab Vedotin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.